---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-26-020402"
form_type: "8-K"
ticker: "AUPH"
cik: "0001600620"
company_name: "Aurinia Pharmaceuticals Inc."
filed_at: "2026-05-11T13:20:50+00:00"
generated_at: "2026-05-11T18:09:00.921848+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Aurinia completes acquisition of Kezar Life Sciences for $6.955/share plus CVR

## Summary
- Offer price: $6.955 cash per share plus one contingent value right (CVR).
- 5,927,580 shares tendered (~80.24% of outstanding) as of Expiration Time on May 8, 2026.
- Merger completed on May 11, 2026 under DGCL Section 251(h); no stockholder vote required.
- Outstanding in-the-money options converted to cash spread plus CVRs; out-of-the-money options cancelled.
- CVR Agreement dated May 11, 2026 with Broadridge as Rights Agent and Fortis Advisors as Representative.

## SEC filing metadata
- accession: 0001140361-26-020402
- form_type: 8-K
- ticker: AUPH
- cik: 0001600620
- company_name: Aurinia Pharmaceuticals Inc.
- filed_at: 2026-05-11T13:20:50+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1600620/000114036126020402/0001140361-26-020402-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1600620/000114036126020402/ef20072568_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-26-020402
- JSON: https://secwatch.observer/filing/0001140361-26-020402.json
- Plain text: https://secwatch.observer/filing/0001140361-26-020402.txt

## Key facts
- M&A Transactions
  Aurinia Pharmaceuticals Inc. completed an acquisition involving Kezar Life Sciences, Inc. for $6.955 in cash, plus one contingent value right (closed 2026-05-11).
  - Action: acquisition
  - Counterparty: Kezar Life Sciences, Inc.
  - Consideration: $6.955 in cash, plus one contingent value right
  - Closing: 2026-05-11
  source text: On May 8, 2026, Parent completed a tender offer for (i) the acquisition of all of the Company’s outstanding shares of common stock, par value $0.001 per share (the “Common Stock”), by Parent through a tender offer (the “Offer”) for a price per share of the Common Stock of: (A) $6.955 in cash (the “Cash Amount”), payable without interest, plus (B) one contingent value right (a “CVR”) (together with the Cash Amount, the “Offer Price”); and (ii) the merger of Merger Sub with and into the Company (the “Merger”), with the Company surviving the Merger.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1600620/000114036126020402/0001140361-26-020402-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.